Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.

Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.

Item

http://www.wikidata.org/entity/Q34444838

Q34444838

about

Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing Harnessing the Microbiome to Enhance Cancer Immunotherapy In vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials' experience.Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children Chemoimmunotherapy.A novel minigene scaffold for therapeutic cancer vaccines Chemotherapy and tumor immunity: an unexpected collaboration Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703.Trial Watch: Experimental Toll-like receptor agonists for cancer therapy Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer.Targeting tumours by adoptive transfer of immune cells.The anticancer immune response: indispensable for therapeutic success?Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.Immunoregulatory dendritic cells to prevent and reverse new-onset Type 1 diabetes mellitus.Carcinoembryonic antigen as a vaccine target.Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.Dendritic cell-based therapy in Type 1 diabetes mellitus.TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy Toll-like receptor 9 agonists as cancer therapeutics.Colorectal cancer vaccines in clinical trials.Dendritic cell therapy for Type 1 diabetes suppression.Chemoimmunotherapy: reengineering tumor immunity.Biological Response Modifier in Cancer Immunotherapy.A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response.Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response.

P2860

Q26825644-8EA2FEAD-13FE-4654-A4A3-AB52A5131AF7 Q28088598-7F3F308D-8FD6-45B6-950F-DD2FEBE18B14 Q28732675-29D7ED07-30E2-4D48-A162-C554C9379C30 Q30278652-19A528E9-51E5-4F5A-AA5D-958AB5369CD1 Q30317446-BF65A532-B07B-410C-987E-ACF2FF710C07 Q33800747-95D179EA-D57E-4E73-A054-32CE2B7C0903 Q34058792-95DDBE46-DE9E-4CD1-B989-6F120B180728 Q34418540-E9E97A09-BCAE-46A5-B256-5EE828B24752 Q34909777-933ED69C-662C-4F1B-82EB-B5F2CFFDED56 Q35635250-3752177F-2343-4853-99C5-5C0336DE1C34 Q36194849-0224D717-529D-44F6-9186-BB8F39C595BB Q36230515-891EBDDE-3722-415A-B575-BA7072180E4A Q36478870-FE667A7F-F7FF-47F0-9F2B-E98B30D71887 Q36677608-5990F952-B222-49EF-AABC-6BF8F013FDD2 Q36886232-5AE4BC15-97CD-4CCD-ABC1-855AB218A6EB Q36897372-1C02E1DA-2785-4CBA-A85D-4E3464D0588D Q37259606-47B13B78-75F0-4661-8D59-AFDE1DA661E7 Q37671730-40CCF469-4D84-43E6-B5A4-2C2E35F6F82F Q37754644-825CD82E-981C-4999-BC03-1ED83598D048 Q37771268-181C3408-FA2A-4CAF-ABE0-1D685CAA6D1C Q37831323-A5C6C93A-C066-4202-AFB6-849F23918FBE Q37892600-399131DD-CA4E-495E-8216-7E0857A65870 Q38059518-62B4CFCD-1A9E-449B-9919-CAADCD0D2277 Q38079749-614CA747-D68D-473B-B931-0A387C898C36 Q38848213-2B8FA314-0396-4246-BD95-151E69BCF700 Q41575936-3102746E-F242-4A92-9465-AC1507CE8039 Q45367630-2FB07BAA-6F77-4F95-A60C-77E5FA58EBF6 Q55073226-9B6B4A25-C613-485D-A971-CA6A917529FB

P2860

Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.

Item

http://www.wikidata.org/entity/Q34444838

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue